Autoimmune gastritis

Pathologist's viewpoint

Irene Coati, Matteo Fassan, Fabio Farinati, David Y. Graham, Robert M. Genta, Massimo Rugge

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Western countries are seeing a constant decline in the incidence of Helicobacter pylori-associated gastritis, coupled with a rising epidemiological and clinical impact of autoimmune gastritis. This latter gastropathy is due to autoimmune aggression targeting parietal cells through a complex interaction of auto-antibodies against the parietal cell proton pump and intrinsic factor, and sensitized T cells. Given the specific target of this aggression, autoimmune gastritis is typically restricted to the gastric corpus-fundus mucosa. In advanced cases, the oxyntic epithelia are replaced by atrophic (and metaplastic) mucosa, creating the phenotypic background in which both gastric neuroendocrine tumors and (intestinal-type) adenocarcinomas may develop. Despite improvements in our understanding of the phenotypic changes or cascades occurring in this autoimmune setting, no reliable biomarkers are available for identifying patients at higher risk of developing a gastric neoplasm. The standardization of autoimmune gastritis histology reports and classifications in diagnostic practice is a prerequisite for implementing definitive secondary prevention strategies based on multidisciplinary diagnostic approaches integrating endoscopy, serology, histology and molecular profiling.

Original languageEnglish (US)
Pages (from-to)12179-12189
Number of pages11
JournalWorld Journal of Gastroenterology
Volume21
Issue number42
DOIs
StatePublished - Nov 14 2015

Fingerprint

Gastritis
Aggression
Histology
Mucous Membrane
Gastric Fundus
Proton Pumps
Intrinsic Factor
Neuroendocrine Tumors
Serology
Secondary Prevention
Helicobacter pylori
Endoscopy
Stomach Neoplasms
Stomach
Adenocarcinoma
Epithelium
Biomarkers
T-Lymphocytes
Pathologists
Antibodies

Keywords

  • Autoimmune gastritis
  • Carcinoids
  • Metaplasia
  • Operative link for gastritis assessment staging

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Coati, I., Fassan, M., Farinati, F., Graham, D. Y., Genta, R. M., & Rugge, M. (2015). Autoimmune gastritis: Pathologist's viewpoint. World Journal of Gastroenterology, 21(42), 12179-12189. https://doi.org/10.3748/wjg.v21.i42.12179

Autoimmune gastritis : Pathologist's viewpoint. / Coati, Irene; Fassan, Matteo; Farinati, Fabio; Graham, David Y.; Genta, Robert M.; Rugge, Massimo.

In: World Journal of Gastroenterology, Vol. 21, No. 42, 14.11.2015, p. 12179-12189.

Research output: Contribution to journalArticle

Coati, I, Fassan, M, Farinati, F, Graham, DY, Genta, RM & Rugge, M 2015, 'Autoimmune gastritis: Pathologist's viewpoint', World Journal of Gastroenterology, vol. 21, no. 42, pp. 12179-12189. https://doi.org/10.3748/wjg.v21.i42.12179
Coati I, Fassan M, Farinati F, Graham DY, Genta RM, Rugge M. Autoimmune gastritis: Pathologist's viewpoint. World Journal of Gastroenterology. 2015 Nov 14;21(42):12179-12189. https://doi.org/10.3748/wjg.v21.i42.12179
Coati, Irene ; Fassan, Matteo ; Farinati, Fabio ; Graham, David Y. ; Genta, Robert M. ; Rugge, Massimo. / Autoimmune gastritis : Pathologist's viewpoint. In: World Journal of Gastroenterology. 2015 ; Vol. 21, No. 42. pp. 12179-12189.
@article{9580baa856aa462b86d67cc261510509,
title = "Autoimmune gastritis: Pathologist's viewpoint",
abstract = "Western countries are seeing a constant decline in the incidence of Helicobacter pylori-associated gastritis, coupled with a rising epidemiological and clinical impact of autoimmune gastritis. This latter gastropathy is due to autoimmune aggression targeting parietal cells through a complex interaction of auto-antibodies against the parietal cell proton pump and intrinsic factor, and sensitized T cells. Given the specific target of this aggression, autoimmune gastritis is typically restricted to the gastric corpus-fundus mucosa. In advanced cases, the oxyntic epithelia are replaced by atrophic (and metaplastic) mucosa, creating the phenotypic background in which both gastric neuroendocrine tumors and (intestinal-type) adenocarcinomas may develop. Despite improvements in our understanding of the phenotypic changes or cascades occurring in this autoimmune setting, no reliable biomarkers are available for identifying patients at higher risk of developing a gastric neoplasm. The standardization of autoimmune gastritis histology reports and classifications in diagnostic practice is a prerequisite for implementing definitive secondary prevention strategies based on multidisciplinary diagnostic approaches integrating endoscopy, serology, histology and molecular profiling.",
keywords = "Autoimmune gastritis, Carcinoids, Metaplasia, Operative link for gastritis assessment staging",
author = "Irene Coati and Matteo Fassan and Fabio Farinati and Graham, {David Y.} and Genta, {Robert M.} and Massimo Rugge",
year = "2015",
month = "11",
day = "14",
doi = "10.3748/wjg.v21.i42.12179",
language = "English (US)",
volume = "21",
pages = "12179--12189",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "42",

}

TY - JOUR

T1 - Autoimmune gastritis

T2 - Pathologist's viewpoint

AU - Coati, Irene

AU - Fassan, Matteo

AU - Farinati, Fabio

AU - Graham, David Y.

AU - Genta, Robert M.

AU - Rugge, Massimo

PY - 2015/11/14

Y1 - 2015/11/14

N2 - Western countries are seeing a constant decline in the incidence of Helicobacter pylori-associated gastritis, coupled with a rising epidemiological and clinical impact of autoimmune gastritis. This latter gastropathy is due to autoimmune aggression targeting parietal cells through a complex interaction of auto-antibodies against the parietal cell proton pump and intrinsic factor, and sensitized T cells. Given the specific target of this aggression, autoimmune gastritis is typically restricted to the gastric corpus-fundus mucosa. In advanced cases, the oxyntic epithelia are replaced by atrophic (and metaplastic) mucosa, creating the phenotypic background in which both gastric neuroendocrine tumors and (intestinal-type) adenocarcinomas may develop. Despite improvements in our understanding of the phenotypic changes or cascades occurring in this autoimmune setting, no reliable biomarkers are available for identifying patients at higher risk of developing a gastric neoplasm. The standardization of autoimmune gastritis histology reports and classifications in diagnostic practice is a prerequisite for implementing definitive secondary prevention strategies based on multidisciplinary diagnostic approaches integrating endoscopy, serology, histology and molecular profiling.

AB - Western countries are seeing a constant decline in the incidence of Helicobacter pylori-associated gastritis, coupled with a rising epidemiological and clinical impact of autoimmune gastritis. This latter gastropathy is due to autoimmune aggression targeting parietal cells through a complex interaction of auto-antibodies against the parietal cell proton pump and intrinsic factor, and sensitized T cells. Given the specific target of this aggression, autoimmune gastritis is typically restricted to the gastric corpus-fundus mucosa. In advanced cases, the oxyntic epithelia are replaced by atrophic (and metaplastic) mucosa, creating the phenotypic background in which both gastric neuroendocrine tumors and (intestinal-type) adenocarcinomas may develop. Despite improvements in our understanding of the phenotypic changes or cascades occurring in this autoimmune setting, no reliable biomarkers are available for identifying patients at higher risk of developing a gastric neoplasm. The standardization of autoimmune gastritis histology reports and classifications in diagnostic practice is a prerequisite for implementing definitive secondary prevention strategies based on multidisciplinary diagnostic approaches integrating endoscopy, serology, histology and molecular profiling.

KW - Autoimmune gastritis

KW - Carcinoids

KW - Metaplasia

KW - Operative link for gastritis assessment staging

UR - http://www.scopus.com/inward/record.url?scp=84947460429&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947460429&partnerID=8YFLogxK

U2 - 10.3748/wjg.v21.i42.12179

DO - 10.3748/wjg.v21.i42.12179

M3 - Article

VL - 21

SP - 12179

EP - 12189

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 42

ER -